Related Experiment Videos
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide
Robert S Meissner1, James J Perkins, Le T Duong
1Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. robert_meissner@merck.com
Bioorganic & Medicinal Chemistry Letters
|December 12, 2001
Abstract:
Mimetics of the RGD tripeptide are described that are potent, selective antagonists of the integrin receptor, alpha(v)beta(3). The use of the 5,6,7,8-tetrahydro[1,8]naphthyridine group as a potency-enhancing N-terminus is demonstrated. Two 3-substituted-3-amino-propionic acids previously contained in alpha(IIb)beta(3) antagonists were utilized to enhance binding affinity and functional activity for the targeted receptor. Further affinity increases were then achieved through the use of cyclic glycyl amide bond constraints.